GASTROENTEROLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Global gastroenterology market is estimated to be valued at USD 35.12 Bn in 2024 and is expected to reach USD 53.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
To learn more about this report, request sample copy
Global gastroenterology market growth is driven by rising demand for minimally invasive procedures. Technological advancements in endoscopy such as high-definition imaging, narrow band imaging, capsule endoscopy, and others boosts the preference for endoscopy among patients and healthcare providers alike. Furthermore, increasing cases of gastrointestinal diseases due to change in lifestyle and eating habits has increased the need for early diagnosis and treatment. Other factors influencing the market growth include increasing healthcare expenditures in emerging economies and rising number of gastrointestinal disorder patients. Growing geriatric population also boosts demand. However, stringent regulatory approvals and high costs of gastrointestinal devices can hamper the market growth during the forecast period.
Increasing incidences of digestive disorders
Global gastroenterology market growth is driven by rising incidences of various digestive disorders across both developed and developing regions of the world. Digestive disorders and conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and liver diseases have become highly prevalent globally, thus, affecting people of all age groups. According to various medical studies and reports, over 25% of adults globally experience symptoms of common digestive issues like acid reflux, bloating or discomfort at least once a month.
High consumption of junk food rich in fats and oils, increasing stress levels, unhealthy lifestyles, pollution, and consumption of alcohol and tobacco has significantly contributed to rising cases of indigestion, acidity, ulcers and other stomach issues. Moreover, genetic predisposition and changing dietary habits has led to increase in incidences of IBD conditions like ulcerative colitis and Crohn's disease especially in developed nations of North America, Western Europe and other developed Asian economies. Due to changing consumer food choices, urbanization and adoption of western lifestyles, there has been rising incidence of digestive disorders in emerging markets. The high prevalence of these conditions boosts need for diagnosis, monitoring and treatment of various gastrointestinal disorders globally, thus, boosting demand for drugs, devices, diagnostic equipment and endoscopy procedures. For Instance, according to a study by Paulo Gustavo Kotze et al., published in the Therapeutic Advances in Gastroenterology journal in July 2020, the incidence and prevalence of ulcerative colitis (UC) in Latin America ranged from 0.04 to 8.00 per 100,000 and 0.23 to 76.1 per 100,000, respectively. This research, along with other studies, suggests that both the prevalence and incidence of ulcerative colitis are on the rise, fueling increased demand in the market
Get actionable strategies to beat competition: Get instant access to report
Rising geriatric population
Growing global geriatric population aged 65 years or older can drive the market growth. According to estimates, their number is expected to double by 2050. According to the data published by United Nations, 1 in 6 people in the world will be over age of 65 years by 2050. Aging is usually accompanied by declining organ functions and rising vulnerability of various age-related diseases. Digestive disorders are highly common among the elderly population due to a number of physiological changes that naturally occur with aging. Factors like reduced stomach acid secretion, reduced digestion and absorption functions of the gastrointestinal tract, reduced gastric motility and delay in bowel movement predispose the elderly to gastrointestinal problems. Common age-related GI issues include gastroesophageal reflux, constipation, incontinence and risks of colon cancer.
Elderly people also tend to have multiple co-morbidities and are on long term medication usage which escalates their susceptibility to drug-induced GI complications. Growing geriatric demographic worldwide has resulted in a massive patient pool requiring gastroenterology treatments. It boosts demand for digestive medications, diagnostic and monitoring services as well as endoscopy devices. Ageing population also leads to increase in gastrointestinal cancers incidence especially in developed nations with Japan, North America and Western Europe home to the largest aged population burden globally. This rising trend of geriatric population can drive the global gastroenterology market growth.
Key Takeaways from Analyst:
Global gastroenterology market growth is driven by rising prevalence of gastrointestinal disorders and increasing adoption of endoscopic procedures. Growing geriatric population susceptible to chronic diseases can also drive the market growth. However, pricing pressure on gastroenterology drugs and lack of awareness in developing nations can hamper the market growth.
North America dominates the market due to technological advancements, favorable reimbursement policies, and growing healthcare expenditure. Presence of key players and rising research activities to develop novel therapies offer growth opportunities in the region. Meanwhile, Asia Pacific exhibits the fastest growth and offers immense potential due to unmet medical needs, rising healthcare standards, and expanding medical tourism.
Rapid urbanization and lifestyle changes increasing obesity and gastrointestinal ailments can offer growth opportunities. However, high costs associated with novel drug development and lengthy approval timelines can hamper the market growth.
Market Challenge - High cost of endoscopy devices
Global gastroenterology market growth can be hampered due to high cost of endoscopy devices. Endoscopy procedures require specialized equipment such as endoscopes, biopsy valves, polypectomy snares and clips, and balloon dilation systems among others. These devices are expensive, which make the overall cost of endoscopy procedures very high. This increased financial burden on patients makes them hesitant to opt for these procedures. The high capital cost of setting up an endoscopy unit further limits the number of gastroenterology centers and doctors that can conduct such procedures. This ultimately restricts greater access of patients to quality healthcare services. Moreover, stringent regulatory frameworks around the world have increased the compliance cost for device manufacturers. All these factors contribute to rising costs of endoscopy devices, which creates affordability challenges especially in developing nations with low healthcare budgets.
Market Opportunity- Increasing adoption of robot-assisted surgical systems
Global gastroenterology market can witness growth opportunities due to increasing adoption of robot-assisted surgical systems. Robotics offers several advantages over conventional laparoscopic surgeries such as high dexterity, 3D visualisation, tremor filtering and motion scaling. These features allow for improved surgical precision, flexibility and control, which enables better clinical outcomes. Gastroenterologists uses robotic platforms for conducting complex procedures such as bariatric surgeries, colorectal surgeries and Heller's myotomy. This boosts demand for surgical robots and associated consumables. Furthermore, robotic systems have potential to make minimally invasive surgeries accessible to sites without trained laparoscopic surgeons, which can expand the reach of quality care. With ongoing technological advancements, robotics can witness greater acceptance in gastrointestinal surgery over the forecast period. This presents lucrative growth opportunities for players operating in the surgical robotics segment.
For instance, according to the data published by HIMSS Media in June 2024, Amrita Hospital in Kochi, Kerala, introduced the G-Gaiter, a robotic gait trainer developed by local startup Gen Robotics, to aid in the rehabilitation of brain and spinal injury survivors. This advanced system, which offers an immersive experience through virtual reality, helps patients improve their walking ability and reduce dependence. The hospital also provides additional services such as neural therapy, non-invasive brain stimulation, and spasticity management alongside the robotic trainer.
Discover high revenue pocket segments and roadmap to it: Get instant access to report
Insights By Drug Type - Mechanisms of action drive biologics/biosimilars segment growth
In terms of drug type, biologics/biosimilars segment is estimated to contribute the highest market share of 30.3% in 2024, owing to their targeted mechanisms of action. These drugs have revolutionized the treatment of various gastrointestinal disorders by directly acting on specific mediators of inflammation. These can precisely modulate the immune system or block certain pathways leading to cytokine release. This allows biologics to provide effective relief from symptoms with fewer side effects as compared to conventional drugs. Anti-TNF inhibitors have proven highly effective for managing inflammatory bowel diseases by neutralizing excess tumor necrosis factor-α, a key driver of inflammation in the gut. Their ability to address the root causes of illnesses rather than just symptoms has made biologics first-line therapies for many chronic GI conditions. Widespread clinical use and favorable outcomes have cemented biologics' dominance in the gastroenterology market.
Insights By Dosage Form - Convenience and compliance boosts oral dosage form
In terms of dosage form, oral segment is estimated to contribute the highest market share of 42.3 % in 2024, due to its convenience and ability to support patient compliance. Swallowing pills is generally more acceptable and less invasive than injections for long-term treatments. This makes the oral route particularly suitable for medications intended to control chronic diseases requiring lifelong medication usage. The ease of oral self-administration at home also facilitates adherence to prescribed dosing regimens. Many GI drug makers prioritize oral formulations to maximize user friendliness. As new entities are developed, oral dosage forms continue to be preferred whenever comparable efficacy to other options can be achieved. Such formulation advantages have positioned oral drugs as the mainstay of therapy for common gastrointestinal disorders.
Insights By Disease Type - Prevalence of inflammatory conditions drives IBD segment
In terms of disease type, inflammatory bowel diseases (IBD) segment is estimated to contribute the highest market share of 41.2% in 2024, owing to rising prevalence worldwide. Crohn's disease and ulcerative colitis are chronic relapsing inflammatory disorders of unknown etiology that predominantly affect the bowel. Recent epidemiological studies indicate growing IBD incidence across both developed and developing regions globally as populations adopt western lifestyles. While genetic factors play a role, experts believe environmental triggers like gut microbiota imbalances and dietary changes can increase IBD burden. These long-lasting conditions demand long-term management with medication. Continued discovery of IBD pathophysiology has enabled improved drug development to reduce symptoms, induce remission, and prevent complications. As one of the most common gastrointestinal ailments, IBD represents a major focus area for gastroenterology therapeutics development.
To learn more about this report, request sample copy
North America has established itself as the dominant region in the global gastroenterology market with an estimated market share of 40.3% in 2024. The region is home to several leading medical device companies with a strong focus on gastroenterology. Companies based in the U.S. such as Boston Scientific, Medtronic and Johnson & Johnson have a major presence globally with their wide gastroenterology product portfolio and strong distribution network within the region as well as internationally.
The region witnesses high adoption of advanced gastroenterology devices and equipment due to favourable reimbursement policies and higher healthcare spending per capita as compared to other regions. Leading medical institutions in the U.S. and Canada are early adopters of new technologies, which helps drive the market for novel gastroenterology products. Furthermore, North America boasts the presence of several contract research organisations which support clinical trials for new devices, drugs and techniques related to gastroenterology.
Asia Pacific region is poised to be the fastest growing market for gastroenterology. Rapid economic growth over the past decade has boosted healthcare infrastructure and expenditure in countries such as China, India and South Korea. Local manufacturers are increasing their R&D efforts to develop affordable devices, catering to the region's needs. Meanwhile, international companies are also aggressively expanding through partnerships with local players to gain access to this lucrative market.
Rising awareness about gastrointestinal diseases and their treatment options can drive the market growth. Aging population and changes in dietary habits have resulted in higher incidences of conditions like gastrointestinal cancers and acid reflux in the Asia Pacific region. This boosts demand for diagnostic and interventional gastroenterology procedures. Furthermore, medical tourism has emerged as an important factor with patients traveling to countries like Thailand and India for affordable treatment of gastrointestinal disorders.
Gastroenterology Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 35.12 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.1% | 2031 Value Projection: | US$ 53.10 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Allied Digestive Health, Boston Scientific, Capital Digestive Care, CRH Medical, Iterative Scopes, Fujifilm Medical, Gastro Health, GI Alliance, Medtronic, Micro-Tech Endoscopy, Motus GI, Olympus, One GI, PE GI Solutions, Peak Gastroenterology Associates, Pentax Medical, Pinnacle GI Partners, Saneso, Surgical Innovations, Wision A.I. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Global gastroenterology market involves medical devices, drugs, and other products used for the treatment of gastrointestinal disorders. This includes devices for endoscopy and colonoscopy such as endoscopes, biopsy forceps, capsules, and others. The market also includes pharmaceutical drugs for treating gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome, and other GI disorders.
Share
About Author
Vipul Patil
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :